key: cord-0971823-drxftps1 authors: Bigio, Jacob; van Gemert, Wayne; Kaiser, Brian; Waning, Brenda; Pai, Madhukar title: Asia emerges as a hotbed of diagnostic innovations for tuberculosis date: 2021-08-25 journal: J Clin Tuberc Other Mycobact Dis DOI: 10.1016/j.jctube.2021.100267 sha: fac66b5754aeca218f81623b9938db9629795425 doc_id: 971823 cord_uid: drxftps1 nan The diagnostic technology landscape for tuberculosis (TB) has never been more varied. Eight products or classes of technologies are recommended by the World Health Organization (WHO) [1] , a further eighteen products are under evaluation by the WHO [2] and dozens more are on the market-a recent landscape analysis found 20 tests for TB infection alone [3] . However, actual use and procurement remains concentrated to a handful of tests. Further, the list of WHO-endorsed products is dominated by companies from Europe and North America. Many of these technologies remain expensive, despite advocacy campaigns for price reductions [4] , or not ideal for low-resource settings, meaning there have been problems scaling up their use in low-and middle-income countries (LMICs) where the TB burden is highest [5] [6] [7] [8] . In general, the field of global health has a problem-an excessive reliance on product and innovations being developed in the Global North that then slowly trickle down to the Global South, where the biggest needs are, and where technologies often have the greatest impact [9] . However, there is capacity in other parts of the world to develop and commercialize diagnostics technologies that should be part of the solution to address global health challenges. This issue has received a lot of attention during the ongoing Covid-19 pandemic, with calls to expand vaccine manufacturing to Africa and other regions, along with TRIPS waiver and technology transfer. In 2019, Indian company Molbio Diagnostics became the first company from an LMIC to receive WHO approval for its TB diagnostic technology [10] . Along with Eiken and Nipro from Japan, it is the only Asian company with a WHO-recommended molecular TB diagnostic. All these products are available for countries to procure via the Global Drug Facility (GDF) [11] , housed at the Stop TB Partnership. By contrast, the WHO's emergency use listing for SARS-CoV-2 in-vitro diagnostics (IVDs) includes several companies from Asia, particularly China, showing that the capacity for diagnostic innovation and manufacturing on the continent is strong [12] . In fact, Asia is also a hotbed of innovation for TB diagnostics, with products on the market which span the complete spectrum of TB diagnosis, from laboratory-based molecular diagnostics to artificial intelligence (AI) for chest x-ray (CXR) interpretation. In 2021, analysis of the results of studies of Qure.ai from India and Lunit from South Korea contributed to the WHO's recommendation for computer-aided detection (CAD) of CXRs [13] . As seen in the current pandemic, having a broad global manufacturing base for diagnostic technologies is highly advantageous. We recently conducted a landscape analysis of the diagnostic technologies for TB produced by companies in four Asian countries-China, India, South Korea, and Japan. Diagnostic technologies were identified through a review of the literature, internet searches and contacts in Asian countries. Where possible, specific contacts within each company were identified, with help from contacts who spoke Chinese and Korean, and emailed questions in English concerning product technical details and national and international regulatory approval. Where specific contacts were unavailable, companies were contacted using generic email addresses or through contact forms on their websites. Data on companies which could not be contacted were compiled using information in the public domain. Data were collected on company and product names, diagnostic method, use case and regulatory approval. Product variants which identify different combinations of drug resistance and are marketed separately were classified as distinct products. Product use cases are as described by the companies. In total, 82 TB diagnostic products were identified from 39 companies [Appendix] . Twelve companies are based in China, seven in India, five in Japan and fifteen in South Korea. Fig. 1 displays company names and diagnostic categories. Most identified products were molecular diagnostics, with a wide range of diagnostic methods and drug resistance detection options available. Diagnostics currently endorsed by the WHO include three chip-based real-time PCR assays by Molbio (Truenat MTB, MTB Plus and MTB-RIF Dx), two line-probe assays (LPAs) by Nipro for detection of resistance to rifampicin and isoniazid (Genoscholar NTM + MDRTB II) and pyrazinamide (Genoscholar PZA-TB II), a loop-mediated isothermal amplification (LAMP) assay by Eiken (Loopamp MTBC Detection Kit), a rapid species identification test from culture by Tauns Laboratories (Capilia TB-Neo) and CAD technologies such as Qure.ai (qXR v2) and Lunit (Lunit Insight CXR). A number of Asian companies make diagnostics for multidrugresistant (MDR) and extensively drug-resistant (XDR) TB. Xiamen Zeesan Biotech makes the MeltPro real-time PCR assays which are approved by the Chinese regulator and can detect resistance to rifampicin, streptomycin, isoniazid, ethambutol, fluroquinolones and second-line injectables. Bioneer makes the Accupower real-time PCR assays, including for MDR and XDR TB; both Optipharm (OPTIMYGENE) and YD diagnostics (MolecuTech) make reverse blot hybridization assays for MDR and XDR TB; and Seegene makes the AllPlex and Anyplex II PCR-based assays for MDR and XDR TB. Other diagnostic methods include isothermal target and probe amplification (RapiDx MTB test by Raplegene), transcription-reverse transcription concerted reaction (TRCRapid-160 M.TB by Tosoh Bioscience), isothermal amplification lateral flow (EasyNAT Diagnostic Kit by Ustar Technologies), simultaneous amplification and testing (SAT-TB by Rendu Biotechnology) and DNA microarray assays (CapitalBio M. Tuberculosis Drug Resistance Detection Array Kit). Interferon-gamma release assays (IGRAs) are made by seven Given the wide array of promising products identified, it is surprising that only a few Asian technologies are included in the WHOrecommended product list. To enter the global health market, technologies have needed to undergo independent, international evaluation studies for policy review and WHO endorsement. Such policy review has not happened with most Asian TB technologies. CE-IVD marking is currently not sufficient to meet these quality assurance criteria. Also, to be internationally competitive, companies must have the ability to provide service and maintenance at the global level. The process for WHO endorsement of TB IVDs is currently changing. The WHO Global Tuberculosis Programme will now focus on the evaluation of classes of TB diagnostic technologies for WHO recommendation, while WHO prequalification will evaluate specific product brands for quality, safety and performance [15] . Companies may also need to meet quality assurance criteria of major donors and procurers such as the Global Fund [16] . An additional recent opportunity for manufacturers of TB diagnostics to get their products into the global marketplace is via the Global Fund's Expert Review Panel for Diagnostics, the approval of which allows for countries to use Global Fund support (the largest international funding source for TB) to procure products that are on the pathway to becoming WHO-approved. We hope more Asian companies can learn from the experience of innovators such as Eiken, Nipro, Molbio, Tauns, Qure.ai and Lunit, and find ways to validate promising technologies further and have them considered for international policy guidance [17] . For WHO endorsement, the current requirements are clearly defined [18] and involve demonstrating analytical and clinical validity, clinical and epidemiologic utility, economic outcomes and operational and qualitative aspects. The expectations for validation data and study design considerations for evaluating different types of TB tests are also published [18] [19] [20] [21] [22] , along with target product profiles [23, 24] . Partnerships with international organizations such as the Foundation for Innovative New Diagnostics (FIND), and initiatives such as the Stop TB Partnership's Accelerator for Impact (a4i) [25] and the recently launched NIHfunded FEND-TB [26] and R2D2 TB Network [27] initiatives, might help Asian innovators better navigate the global policy process. Beyond validation and inclusion in global policy, there is a need to also address other barriers to product uptake and scale, including pricing that is suitable for LMICs, capacity for service and maintenance, donor support for scale-up, and better guidance on when or how to switch from one product to another. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. World Health Organization, WHO consolidated guidelines on tuberculosis World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization Tests for tuberculosis infection: landscape analysis Time for $5: GeneXpert diagnostic tests. Geneva: Médecins Sans Frontières Tuberculosis innovations mean little if they cannot save lives. eLife Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from Global Health Technologies: Time To Re-Think The 'Trickle Down' Model World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization Stop TB Partnership/Global Drug Facility World Health Organization, WHO Emergency Use Listing for In vitro diagnostics (IVDs) Detecting SARS-CoV World Health Organization, WHO consolidated guidelines on tuberculosis List of TB Diagnostic test kits and equipments classified according to the Global Fund Quality Assurance Policy Public announcement to TB in vitro diagnostics manufacturers, procurement agencies and national TB programmes on inclusion of WHO Prequalification for TB in vitro diagnostics The Global Fund, Global Fund quality assurance policy for diagnostics products How China can reshape the mechanics of global healthcare innovation by taking on Tuberculosis: An interview with Professor Madhukar Pai Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting World Health Organization. Target product profile for next-generation drug-susceptibility testing at peripheral centres. Geneva: World Health Organization Accelerator for Impact (a4i)